|
Originally published In Press as doi:10.1074/jbc.M208453200 on September 18, 2002
J. Biol. Chem., Vol. 277, Issue 49, 47613-47618, December 6, 2002
Function of Region I and II Adhesive Motifs of
Plasmodium falciparum Circumsporozoite Protein in
Sporozoite Motility and Infectivity*
Rita
Tewari ,
Roberta
Spaccapelo §,
Francesco
Bistoni§,
Anthony A.
Holder¶, and
Andrea
Crisanti
From the Imperial College of Science, Technology and
Medicine, Imperial College Road, London SW7 2AZ, United Kingdom, the
§ Department of Experimental Medicine, University of
Perugia, 06100, Italy, and the ¶ Division of Parasitology,
National Institute for Medical Research, The Ridgeway, London NW7 1AA,
United Kingdom
Received for publication, August 19, 2002, and in revised form, September 12, 2002
 |
ABSTRACT |
The circumsporozoite protein of Plasmodium
falciparum contains two conserved motifs (regions I and II) that
have been proposed to interact with mosquito and vertebrate host
molecules in the process of sporozoite invasion of salivary glands and
hepatocytes, respectively. To study the function of this protein we
have replaced the endogenous circumsporozoite protein gene of
Plasmodium berghei with that of P. falciparum
and with versions lacking either region I or region II. We show here
that P. falciparum circumsporozoite protein functions in
rodent parasite and that P. berghei sporozoites carrying
the P. falciparum CS gene develop normally, are motile, invade mosquito salivary glands, and infect the vertebrate host. Region
I-deficient sporozoites showed no impairment of motility or infectivity
in either vector or vertebrate host. Disruption of region II abolished
sporozoite motility and dramatically impaired their ability to invade
mosquito salivary glands and infect the vertebrate host. These data
shed new light on the role of the CS protein in sporozoite motility and infectivity.
 |
INTRODUCTION |
The malaria sporozoite has the unique ability to selectively
invade the salivary glands of the mosquito vector and the vertebrate host cells (1). At this developmental stage the surface of the parasite
is mainly covered by the circumsporozoite
(CS)1 protein (2-4). In all
malaria species the CS protein shows a similar structural organization
consisting of a variable central region of repeats and two highly
conserved motifs, regions I and II, placed at the amino- and
carboxyl-terminal ends of the molecule, respectively. Region I is based
around the short amino acid motif KLKQP. This motif is identical in all
malaria parasites so far described in mammals (5). In the avian
parasite such as Plasmodium gallinaceum the CS
protein lacks region I. Region II is a 20-amino acid motif
EWSXCXVTCGXG(V/I)XXRX(K/R)
that shares sequence homologies to the type 1 repeat of human
thrombospondin (TSP) (6). One to seven copies of this motif
have now been found in a number of proteins involved in the complement
pathway (properdin, C6, C7, C8A, C8B, and C9) as well as adhesive
extracellular matrix proteins like ADAMTS, mindin, F-spondin, or
SCO-spondin and micronemal proteins of apicomplexan parasites (7-13).
One of these micronemal proteins, the thrombospondin-related adhesive
protein (TRAP), contains a single TSP type 1 repeat and is expressed at
the sporozoite stage of malaria parasites (8, 14).
Several proteins containing a TSP type 1 motif, including TRAP have the
ability to selectively recognize glycosaminoglycans (GAGs) (12, 13, 15,
16). Similarly, recombinant forms of CS protein, as well as synthetic
peptides encompassing region II, specifically bind to highly sulfated
GAGs such as heparin and heparan sulfate (11, 17-21). It is intriguing
that sporozoites express two distinct molecules, TRAP and CS protein,
both containing a TSP type 1 repeat and having similar adhesive
properties. The reasons for this are not clear. Gene disruption and
biochemical evidence indicate that TRAP functions as a parasite
receptor molecules and plays a crucial role in gliding, a form of
substrate-dependent forward locomotion intimately linked to
the process of sporozoite invasion of mosquito salivary glands and
vertebrate host cells (22-24). The function of the CS protein is far
less well established. The location on the parasite surface, the
presence of the highly conserved region I and II sequences, and the
adhesive property for GAGs have suggested that the CS protein ought to
play an important role in the processes of sporozoite recognition and
invasion of mosquito salivary glands and vertebrate host cells (17, 18, 25-27). Disruption of the CS gene did not add to the knowledge on the
CS protein as receptor in the sporozoites. Plasmodium
berghei parasites in which the CS gene has been targeted fail to
develop into mature oocysts, and very few sporozoites if any are
produced (28). The elucidation of the function of CS protein and its conserved motifs, regions I and II, would be of great importance for a
better understanding of sporozoite interactions with mosquito salivary
glands and vertebrate host cells. This information will also be useful
to unravel functional relationships between TRAP and CS protein.
To examine the role of CS protein and its conserved motifs, we have
generated transgenic P. berghei parasites in which the endogenous CS protein gene (PbCS) has been replaced with
either the P. falciparum CS protein gene (PfCS)
or with versions of PfCS without either region I or II.
These parasites were studied throughout development in the mosquito as
well as for their ability to infect mice.
 |
EXPERIMENTAL PROCEDURES |
DNA Constructs--
The targeting constructs pPfCSP,
pPfCSP(RI ), and PfCSP(RII ) used in this
study contained the following structural elements: (i) a
5'-untranslated region (UTR) of the PbCS gene encompassing nucleotides 1-1130 immediately upstream of the PbCS start
codon; (ii) the WT or mutated versions of PfCS coding
sequence (1660 bp) from Plasmodium falciparum Wellcome
strain linked to 250 nucleotides of its 3'-UTR; and (iii) the 3'-UTR
sequence of PbCS gene encompassing nucleotides 1-1150
downstream of its stop codon in which the DHFR-TS transcription unit
(5400 bp) was inserted at its HindIII site (+302)
(29). Deletions of region I (KLKQP) and region II (WSPCSVTCGNGIQVRIK) were introduced in the PfCS coding sequence by site-directed
mutagenesis (Sculptor in vitro mutagenesis kit, Amersham
Biosciences) and verified by sequence analysis.
Parasite Transformation--
The P. berghei ANKA
strain (clone 2.34) was transformed in electroporation experiments by
using 50-70 µg of a DNA insert. Plasmid DNA was digested to release
the targeting inserts (~9.2 kb) from the plasmid backbone and
purified by gel electrophoresis and phenol/chloroform extraction.
Purified schizonts were transformed with the constructs pPfCSP,
pPfCSP(RI ), and pPfCSP(RII ) using a Bio-Rad
electroporator set at 1.1 kV and 25 microfarads and subsequently
injected intravenously in phenylhydrazine (to increase
reticulocyte production)-treated Wistar rats as described previously (29). Pyrimethamine-resistant parasites were selected in the
recipient rats and BALB/c mice as described previously (29) and cloned
in BALB/c mice by limiting dilution.
Southern Blot Analysis--
Genomic DNA was isolated from
parasites as previously described (29). For Southern blot analysis 5 µg of genomic DNA was digested with EcoRV, separated on
agarose gel, and blotted onto a nylon Hybond-N+ membrane
(Amersham Biosciences). The following DNA fragments were used as
probes: (a) a 1.1-kb 5'-UTR sequence of PbCS
amplified using the primers 5'-UTR1CS (TTT AAA TAT ATG CGT GTA TAT ATA
G) and 5'-UTR2CS (CGC TTT TAC TTT GTC CAG GTA TTA TGC); (b)
a-666 bp fragment amplified from PbCS coding sequence with
the primers CSFor81 (CCA GGA TAT GGA CAA AAT AAA) and CSRev83 (ATT GTT
ATT ACC ACC TGG C); (c) a 510-bp fragment amplified from
PfCS with the primers PFCS3 (GGA CAA GGT CAC AAT ATG CC) and
PFCS5 (CAT ATA TAT TTC TAC AAT TAA TCG); (d) a 1.1-kb
fragment amplified from the 3'-UTR sequence of PbCS gene
with the primers 3'-UTR1CS (ATA AAC ATT ACG CAT GAT TAT A) and
3'-UTR2CS (GAG TAC TCA CGA ATC CGA AAT AAG); and (e) a
520-bp fragment amplified from the DHFR-TS gene with the
primers TgFor123 (AGA GGG GCA TCG GCA TCA AC) and TgRev124 (TTG AAA GAA
TGT CAT CTC CG). All hybridization experiments were carried out as
described (24). Parasite chromosomes were separated by pulse-field gel
electrophoresis using a CHEF DRIII apparatus (Bio-Rad) set at 60-600 s
and 4 V/cm and run for 48 h. The gel was blotted and hybridized
with probes b and c to detect PbCS and PfCS sequences.
Parasite Development in the Mosquito--
Anopheles
stephensi mosquitoes (strain sd 500) were fed for 1 h on WT
and transgenic infected Balb/c mice having a parasitemia ranging from 6 to 7%. Mosquitoes were dissected at day 8, 14, and 21 post infection
and processed to reveal the presence of oocysts and sporozoites in the
guts and salivary glands. The dissection procedures and parasite counts
were carried out in RPMI 1640 medium without serum.
Parasite Infectivity in Mice--
Increasing numbers of WT and
transgenic salivary gland and gut sporozoites were resuspended in RPMI
and injected intravenously in the tail vein of naïve C57BL/6
(minimum age of 6 weeks). At regular time intervals (12 h) after
sporozoite injection (for up to day 15), blood samples were withdrawn
from the tail of injected animals and analyzed on Giemsa-stained thin
smears to reveal the presence of parasites. The pre-patent period was
assessed by determining the number of days between sporozoite
injection, and the time when at least three to five parasites could be
detected by analyzing a minimum of 10,000 erythrocytes on
Giemsa-stained blood smears.
Immunofluorescence--
Freshly dissected 21-day post-infection
oocyst sporozoites resuspended in RPMI were spotted onto microscope
multiwell slides. Sporozoites were incubated for 30 min either at room
temperature or at 37 °C. At the end of the incubation time the
excess of medium was removed, and slides were air-dried and kept at
20 °C. For immunofluorescence (IF) analysis the parasite samples
were fixed in 1% formaldehyde in phosphate-buffered saline.
Nonspecific binding was prevented by treating the slides for 30 min
with phosphate-buffered saline containing 1% bovine serum albumin and
0.05% Triton X-100. Sporozoites were incubated for 1 h with
either the monoclonal antibody 7E4 directed against PbTRAP (24) or
monoclonal antibody 3D11 directed against PbCS (2) or the rabbit serum
NANP raised against a fusion protein between PfCS and
PMMSA (30). The slides were subsequently incubated with
fluorescein isothiocyanate-labeled secondary antibodies (goat
anti-mouse or anti-rabbit immunoglobulins, Becton Dickinson). IF
analysis was carried out by using a Leica TCS SP 2 confocal microscope.
 |
RESULTS |
Development of Transgenic Parasites--
We have designed DNA
constructs to achieve the deletion of the endogenous PbCS,
the insertion of wild type (WT) or mutated PfCS versions,
and the insertion of the selectable marker transcription unit, in a
single transformation event. This strategy has several advantages. It
generates non-reversible molecular events in contrast to gene targeting
mediated by single crossover homologous recombination (22) and
overcomes the parasite repair mechanism that has been shown in P. berghei to correct small mutations within the targeted gene with
WT sequences (31). The replacement of the endogenous CS protein gene
with a largely divergent homologous gene allows the structure-function
analysis to be focused on the conserved motifs, thus
facilitating the study of the transgenic parasites carrying a deletion
of either region I or II. Moreover, the detection of the PfCS protein
in P. berghei sporozoites offers the opportunity to analyze
the expression of the replaced gene in single sporozoites. The
construct pPfCSP contained the entire PfCS coding sequence, whereas the constructs pPfCSP(RI ) and
pPfCSP(RII ) carried a PfCS sequence without
region I or II, respectively (Fig.
1A). Transformation,
selection, and cloning experiments (24, 29) yielded the transgenic
parasite clones CSP-9 (replacement with PfCS),
CSP(RI )-6 (replacement with PfCS without
region I) and CSP(RII )-7 (replacement with
PfCS without region II). Southern blot analysis demonstrated
that the three targeting constructs correctly integrated in the
transgenic parasites thereby placing the PfCS coding
sequences under the control of the endogenous PbCS
regulatory sequences and directing the downstream insertion of the
selectable marker DHFR-TS (Fig. 1B). Probe a, encompassing
1.1 kb of the 5'-UTR of PbCS, hybridized with a single band
of 4.2 kb in the digest of WT parasites in agreement with the predicted
position of the EcoRV sites in the PbCS locus.
The same probe hybridized with a single band of about 4.8 kb in the
EcoRV digest of the transgenic parasites. The size shift is
due to the insertion of PfCS coding sequence and its 3'-UTR
that together exceeded the size of the endogenous PbCS gene
by 560 nucleotides. This result was confirmed by the observation that
probe b, encompassing the coding sequence of PbCS,
hybridized with a single band of 4.2 kb in the WT digest but failed to
show any reactivity with the DNA of the transgenic parasites. Probe c,
encompassing the coding sequence of PfCS, hybridized only
with a 4.8-kb band in the transgenic parasite digests. The
hybridization pattern of probe d, encompassing the coding sequence of
DHFR-TS, and probe e, encompassing the 3'-UTR of PbCS,
indicated that the DHFR-TS transcription unit had correctly integrated
in CSP-9, CSP(RI )-6, and CSP(RII )-7 (Fig.
1B). Chromosome blots hybridized with probes b and c confirmed that, in the transgenic parasites, the PfCS coding
sequences had selectively replaced the endogenous PbCS gene
on chromosome 4 (Fig. 1C). The integrity of the inserted DNA
was confirmed by PCR and sequence analysis (data not shown).

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 1.
The PbCS locus and the
integration of PfCS. A, map of the
pPfCSP construct and schematic representation of the WT and targeted
PbCS locus. To direct the 5' recombination event, a 1.1-kb
5'-UTR sequence (light gray box) of PbCS
(dashed box pointing upward) was inserted in front of the
1.6-kb WT PfCS coding sequence linked to 250 nucleotides of
its 3'-UTR (dark gray box). A 302-bp sequence corresponding
to the PbCS 3'-UTR (black box) was placed
downstream of PfCS to minimize unforeseen problems in
transcriptional regulation and stability. A further 848 bp of the
PbCS 3'-UTR (dashed box pointing downward) was
inserted downstream of the DHFR-TS transcription unit (white
box), to provide the end for the 3' recombination event.
E indicates the position of the EcoRV cleavage
sites. Thick black lines (a-e) indicate the
position of the probes used in Southern blot experiments. The
lower panel shows the alignment of PbCS protein region I and
II motifs with the corresponding PfCS protein sequences carried by the
transformation constructs pPfCSP, pPfCSP(RI ), and
pPfCSP(RII ). Deletions of region I (KLKQP) and region II
(WSPCSVTCGNGIQVRIK) were introduced in the PfCS coding
sequence by site-directed mutagenesis. B, Southern blot
analyses of the parasites. Genomic DNA from WT and transgenic parasites
was digested with EcoRV, and hybridized with five different
probes denoted a-e below each panel, to ascertain the
correct integration of the constructs. Size markers are in kilobases
(kb). C, Southern blot analyses of chromosomes
from WT and transgenic parasites separated by pulse-field gel
electrophoresis. The position of chromosome 4 migration is indicated by
an arrow.
|
|
Development of the Transgenic Parasites in the Mosquito--
Blood
stage parasites from CSP-9, CSP(RI )-6, and
CSP(RII )-7 replicated normally in mice and generated
gametocytes that developed into fertile gametes and morphologically
normal ookinetes (data not shown). A. stephensi mosquitoes
were fed on mice infected with these three different transgenic
parasites. The development of the parasite in the mosquito was
monitored starting from day 8 post infection, examining the oocyst
where the expression of CS is first detected. Sporozoite-containing
oocysts were detected in the gut at day 14 post infection (Fig.
2A). In four independent experiments CSP-9, CSP(RI )-6, and
CSP(RII )-7 generated an average of 78, 104, and 67 oocysts per gut, respectively, values that were very similar to those
observed for WT P. berghei parasites (Table
I). This indicates that, unlike a
CS knock-out where no sporozoites were detected in oocysts
(28), parasite development in the gut was not affected by the
replacement with PfCS gene or with the variants without
regions I or II. Compared with WT parasites, clones CSP-9 and
CSP(RI )-6 showed a 10- to 16-fold reduction in the number
of salivary gland sporozoites, whereas a 290-fold reduction was
observed with CSP(RII )-7 parasites (Table I). P. falciparum and P. berghei WT sporozoites infected
equally well the salivary glands of the mosquitoes utilized in this
study (data not shown) thus arguing against the possibility that the
reduced infectivity of the transgenic sporozoites is due to a salivary
gland refractoriness of our laboratory mosquito strain for the selected
PfCS coding sequence. The infectivity of CSP-9 sporozoites
was high enough to assess the effect of the deletion of regions I and
II. Compared with CSP-9 and CSP(RI )-6,
CSP(RII )-7 showed a greater than 95% reduction in the
number of salivary gland sporozoites; statistical analysis indicated
that such a difference is significant (p < 0.05). We
further investigated the phenotype of the transgenic sporozoites by
analyzing the expression of PfCS protein by immunofluorescence (IF) and
by assessing their ability to glide on glass surfaces, which reflects
their motility status. This analysis demonstrated an initial normal
location of the CS protein in all transgenic parasites. Freshly
dissected gut sporozoites from each of the transgenic clones showed a
uniform and bright surface staining when incubated with an antiserum
against PfCS protein (data not shown). Following incubation at 37 °C
for 1 h, more than 50% of CSP-9 and CSP(RI )-6 gut
sporozoites (21 days post infection) showed CS protein-reactive trails
from gliding on a glass surface (Fig. 2B). The shape of the
trails, which consist of the immunoreactive CS material, indicated that
about 10% of the sporozoites were able to form one or more complete
loops, whereas the rest of the sporozoites left trails of variable
shape and length. The frequencies of motile parasites were similar for
WT, CSP-9, and CSP(RI )-6 sporozoites and in agreement
with previous reports on the motility of gut sporozoites (14). In
contrast, CSP(RII )-7 sporozoites did not show any form of
gliding motility upon temperature switch to 37 °C. At this
temperature the uniform PfCS protein surface staining observed at
25 °C was replaced by clumps of immunoreactive material either
outside the parasite body or in proximity to its surface (Fig.
2B). The inability of CSP(RII )-7 sporozoites
to glide was analyzed further by IF to study the expression and the
location of TRAP, a micronemal parasite-encoded molecule that is
implicated in sporozoite motility (22-24). TRAP expression was not
altered in CSP(RII )-7 sporozoites, a typical TRAP
staining pattern with antibody-reactive material distributed within the
cytoplasm both anterior and posterior to the nucleus (14) was observed
in WT and in all transgenic sporozoites (Fig. 2B).

View larger version (49K):
[in this window]
[in a new window]
|
Fig. 2.
Oocyst development and sporozoite
motility. A, phase-contrast microphotographs of
mosquito guts containing WT and transgenic parasite oocysts, showing no
significant morphological differences. B, confocal
immunofluorescence (IF) microphotographs of WT and
transgenic gut sporozoites incubated at 37 °C and developed using
antibodies directed against PbCS protein, PfCS protein, and PbTRAP.
Motile sporozoites shed circular trails of material recognized by
antibodies directed against CS.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Parasite development in mosquitoes
Values represent the mean ± S.E. of four different independent
experiments, each with a minimum of 50 mosquitoes.
|
|
Infectivity of the Transgenic Parasites for the Vertebrate
Host--
The role of regions I and II for parasite infectivity of the
mammalian host was investigated following intravenous injection into
naïve C57BL/6 mice of either salivary gland or gut sporozoites both collected at day 21 post infection. In addition, infected mosquitoes carrying the different transgenic parasites were allowed to
feed on naïve mice. A blood stage infection was initiated in a
substantial fraction of the mice by as few as 100 WT salivary gland
sporozoites (Table II), whereas with 1000 sporozoites all mice were infected. When 5000 sporozoites were
inoculated, the number of days between injection of sporozoites and the
first appearance of the parasites in the blood (the pre-patent period), decreased from 5.0 to 3.5 days. Identical rates of infection and pre-patent periods were observed by injecting similar numbers of CSP-9
and CSP(RI )-6 salivary gland sporozoites (Table II).
CSP(RII )-7 sporozoites always failed to infect the mice
(Table II). The infectivity of gut sporozoites was much less efficient
than salivary gland sporozoites. This observation is in agreement with
earlier reports showing that gut sporozoites are less infective than
salivary gland sporozoites (32). Although a fraction of mice was
infected with WT, CSP-9, and CSP(RI )-6 gut sporozoites,
the region II-deleted parasites CSP(RII )-7 always failed
to infect the mice even after the injection of 1 million sporozoites
(Table III). Similarly,
CSP(RII )-7-infected mosquitoes failed to initiate
infection in the mice after blood feeding. These findings clearly
indicate that, although the deletion of region I of CS protein does not
impair sporozoite infectivity, region II has a critical role in this
process.
 |
DISCUSSION |
Our data have important implications for understanding the
function of the CS protein and its domains in the process of sporozoite motility and infectivity. All transgenic parasite lines developed normally to the oocyst stage. CSP-9 sporozoites infected mosquito salivary glands less efficiently than WT P. berghei
sporozoites. Possibly the sequence changes introduced outside the
conserved region I and II by replacing PbCS with
PfCS could have reduced the ability of the PfCS protein to
function optimally within the P. berghei background during
sporozoite invasion of A. stephensi salivary glands. The
removal of region I did not modify CSP(RI )-6 sporozoite
motility and infectivity for mosquito salivary gland compared with
CSP-9 parasites. This last finding would rule out a role of this motif
in the process of sporozoite recognition of a mosquito salivary gland
ligand. Such a conclusion is in agreement with the notion that the CS
protein expressed by CSP(RI )-6 sporozoites has a
structural organization similar to the P. gallinaceum CS
protein (5). The absence of region I in P. gallinaceum CS protein does not affect parasite development into
oocyst and sporozoite invasion of salivary glands.
The removal of region II almost abolished the ability of sporozoites to
infect salivary glands. A role of region II in the process of CS
protein recognition of salivary gland ligands could not be inferred on
the basis of these findings. The deletion of this sequence also
abolished sporozoite gliding thus making it difficult to assess whether
the impairment of salivary gland invasion was the direct consequence of
disrupting a crucial receptor-ligand interaction or indirectly due to
the lack of motility. CSP(RII )-7 sporozoites did not
glide upon temperature switch to 37 °C as indicated by the lack of
CS protein trails and the clumps of CS-reactive material along the
surface and outside the parasite body. In these sporozoites the flow of
CS protein from the apical complex to the caudal end of the parasite
appeared to be replaced by a spatial, uncoordinated capping process.
The phenotype of CSP(RII )-7 sporozoites sheds new light
on the composition and the function of the sporozoite locomotion
machinery. TRAP has been previously hypothesized to function in the
process of sporozoite motility by linking host ligands bound to its
adhesive domains (TSP type 1 repeat sequence and A domain) with the
parasite actin-myosin motor (23, 24, 33). Notably, TRAP knock-out P. berghei sporozoites do not move (22). This phenotype is
identical to that of CSP(RII )-7 sporozoites thus
indicating that TRAP alone is necessary but not sufficient for
sporozoite motility. Our findings now demonstrate that for sporozoites
to move TRAP must be functionally coupled to a CS protein containing an
intact region II. This could be achieved through a direct interaction
or be mediated by additional parasite molecular partners. The deletion
of region II in the CS protein could impair sporozoite motility either
by disrupting these interactions or by impairing the ability of the CS
protein to directly mediate attachment of the sporozoites to host
ligands. The disruption of region II also abolished sporozoite
infectivity for the vertebrate host as shown by the observation that
CSP(RII )-7 sporozoites always failed to infect the mice
(Table II).
CSP-9 and CSP(RI )-6 sporozoites infected C57BL/6 mice
equally well as the parental WT parasites thus demonstrating that the PfCS protein is able to complement the activity of the endogenous P. berghei CS protein very efficiently. The disruption of
region I did not impair sporozoite infectivity in the vertebrate host. This was a surprise, because region I is present in the CS protein of
mammalian parasite and is absent in avian parasites. Sporozoites of
mammalian parasites infect host hepatocytes, whereas avian parasites
selectively invade and develop inside the macrophages. This correlation
between CS protein structure and sporozoite infectivity for different
host cell types has suggested a role of region I in sporozoite
recognition and entry of vertebrate hepatocytes. If this were the case
our findings indicate that this function can be complemented by region
II at least in the parasite-vertebrate host combination utilized in
this study. This would be in agreement with previous reports showing
that the ligand of region I could be a GAG-related molecule sharing
structural similarities with the ligand of region II (21, 34, 35).
The P. falciparum CS protein has been regarded as one of the
best vaccine candidates for malaria (1, 36). Transgenic P. berghei sporozoites expressing P. falciparum CS protein
represent a unique tool to systematically assess formulation, regimen,
and molecular composition of a human malaria vaccine using a high throughput animal experimental model.
 |
ACKNOWLEDGEMENTS |
We thank Dr. C. K. Cemal and Dr. F. Gouze for the supply of materials and assistance; I. Morris, Dr. M. Arai, and D. Bacon for illustrations and photographs. We are also
grateful to Dr. K. Robson and Dr. L. Miller for discussing the
manuscript and Dr. U. Frevert for disclosing data before publication.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.:
44-207-594-5426; Fax: 44-207-594-5439; E-mail: acrs@ic.ac.uk.
Published, JBC Papers in Press, September 18, 2002, DOI 10.1074/jbc.M208453200
 |
ABBREVIATIONS |
The abbreviations used are:
CS, circumsporozoite;
TSP, thrombospondin;
TRAP, thrombospondin-related
adhesive protein;
GAG, glycosaminoglycan;
UTR, untranslated repeat;
WT, wild type;
DHFR-TS, dihydrofolate reductase-thymidylate
synthase;
IF, immunofluorescence.
 |
REFERENCES |
| 1.
|
Nussenzweig, V.,
and Nussenzweig, R. S.
(1989)
Adv. Immun.
45,
283-334[Medline]
[Order article via Infotrieve]
|
| 2.
|
Yoshida, N.,
Nussenzweig, R. S.,
Potocnjak, P.,
Nussenzweig, V.,
and Aikawa, M.
(1980)
Science
207,
71-73[Abstract/Free Full Text]
|
| 3.
|
Aikawa, M.,
Yoshida, N.,
Nussenzweig, R. S.,
and Nussenzweig, V.
(1981)
Trans. R. Soc. Trop. Med. Hyg.
126,
2494-2495
|
| 4.
|
Yoshida, N.,
Potocnjak, P.,
Nussenzweig, V.,
and Nussenzweig, R. S.
(1981)
J. Exp. Med.
154,
1225-1236[Abstract/Free Full Text]
|
| 5.
|
McCutchan, T. F.,
Kissinger, J. C.,
Touray, M. G.,
Rogers, M. J., Li, J.,
Sullivan, M.,
Braga, E. M.,
Krettli, A. U.,
and Miller, L. H.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
11889-11894[Abstract/Free Full Text]
|
| 6.
|
Lawler, J.,
and Hynes, R. O.
(1986)
J. Cell Biol.
103,
1635-1648[Abstract/Free Full Text]
|
| 7.
|
Goundis, D.,
and Reid, K. B.
(1988)
Nature
335,
82-85[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Robson, K. J. H.,
Hall, J. R. S.,
Jennings, M. W.,
Harris, T. J. R.,
Marsh, K.,
Newbold, C. I.,
Tate, V. E.,
and Weatherall, D. J.
(1988)
Nature
355,
79-82
|
| 9.
|
Gobron, S.,
Monnerie, H.,
Meiniel, R.,
Creveaux, I.,
Lehmann, W.,
Lamalle, D.,
Dastugue, B.,
and Meiniel, A.
(1996)
J. Cell Sci.
109,
1053-1061[Abstract]
|
| 10.
|
Kuno, K.,
Iizasa, H.,
Ohno, S.,
and Matsushima, K.
(1997)
Genomics
46,
466-471[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Gantt, S. M.,
Clavijo, P.,
Bai, X.,
Esko, J. D.,
and Sinnis, P.
(1997)
J. Biol. Chem.
272,
19205-19213[Abstract/Free Full Text]
|
| 12.
|
Adams, J. C.,
and Tucker, R. P.
(2000)
Dev. Dyn.
218,
280-299[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Adams, J. C.
(2001)
Annu. Rev. Cell Dev. Biol.
17,
25-51[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Robson, K. J. H.,
Frevert, U.,
Reckmann, I.,
Cowan, G.,
Beier, J.,
Scragg, I. G.,
Takehara, K.,
Bishop, D. H. L.,
Pradel, G.,
Sinden, R. E.,
Saccheo, S.,
Müller, H. M.,
and Crisanti, A.
(1995)
EMBO J.
14,
3883-3894[Medline]
[Order article via Infotrieve]
|
| 15.
|
Rostand, K. S.,
and Esko, J. D.
(1997)
Infect. Immun.
65,
1-8[Medline]
[Order article via Infotrieve]
|
| 16.
|
Bernfield, M.,
Gotte, M.,
Park, P. W.,
Reizes, O.,
Fitzgerald, M. L.,
Lincecum, J.,
and Zako, M.
(1999)
Annu. Rev. Biochem.
68,
729-777[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Pancake, S. J.,
Holt, G. D.,
Mellouk, S.,
and Hoffman, S. L.
(1992)
J. Cell Biol.
117,
1351-1357[Abstract/Free Full Text]
|
| 18.
|
Frevert, U.,
Sinnis, P.,
Cerami, C.,
Shreffler, W.,
Takacs, B.,
and Nussenzweig, V.
(1993)
J. Exp. Med.
177,
1287-1298[Abstract/Free Full Text]
|
| 19.
|
Sinnis, P.,
Clavijo, P.,
Fenyö, D.,
Chait, B. T.,
Cerami, C.,
and Nussenzweig, V.
(1994)
J. Exp. Med.
180,
297-306[Abstract/Free Full Text]
|
| 20.
|
Sinnis, P.,
and Sim, K.-L. B.
(1997)
Trends Microbiol.
5,
52-58[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Ying, P.,
Shakibaei, M.,
Patankar, M. S.,
Clavijo, P.,
Beavis, R. C.,
Clark, G. F.,
and Frevert, U.
(1997)
Exp. Parasitol.
85,
168-182[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Sultan, A. A.,
Thathy, V.,
Frevert, U.,
Robson, K. J.,
Crisanti, A.,
Nussenzweig, V.,
Nussenzweig, R. S.,
and Menard, R.
(1997)
Cell
90,
511-522[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Spaccapelo, R.,
Naitza, S.,
Robson, K. J.,
and Crisanti, A.
(1997)
Lancet
350,
335[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Wengelnik, K.,
Spaccapelo, R.,
Naitza, S.,
Robson, K. J.,
Janse, C. J.,
Bistoni, F.,
Waters, A. P.,
and Crisanti, A.
(1999)
EMBO J.
18,
5195-5204[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Cerami, C.,
Frevert, U.,
Sinnis, P.,
Takacs, B.,
Clavijo, P.,
Santos, P.,
and Nussenzweig, V.
(1992)
Cell
70,
1021-1033[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Sidjanski, S. P.,
Vanderberg, J. P.,
and Sinnis, P.
(1997)
Mol. Biochem. Parasitol.
90,
33-41[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Pinzon-Ortiz, C.,
Friedman, J.,
Esko, J.,
and Sinnis, P.
(2001)
J. Biol. Chem.
276,
26784-26791[Abstract/Free Full Text]
|
| 28.
|
Menard, R.,
Sultan, A. A.,
Cortes, C.,
Altszuler, R.,
van Dijk, M. R.,
Janse, C. J.,
Waters, A. P.,
Nussenzweig, R. S.,
and Nussenzweig, V.
(1997)
Nature
385,
336-340[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Waters, A. P.,
Thomas, A. W.,
van Dijk, M. R.,
and Janse, C. J.
(1997)
Methods
13,
134-147[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Holder, A. A.,
Lockyer, M. J.,
and Hardy, G. W.
(1988)
Parasitology
97,
373-382
|
| 31.
|
Nunes, A.,
Thathy, V.,
Bruderer, T.,
Sultan, A. A.,
Nussenzweig, R. S.,
and Menard, R.
(1999)
Mol. Cell. Biol.
19,
2895-2902[Abstract/Free Full Text]
|
| 32.
|
Vanderberg, J. P.
(1975)
J. Parasitol.
61,
43-50[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Morrissette, N. S.,
and Sibley, L. D.
(2002)
Microbiol. Mol. Biol. Rev.
66,
21-38[Abstract/Free Full Text]
|
| 34.
|
Rathore, D.,
McCutchan, T. F.,
Garboczi, D. N.,
Toida, T.,
Hernaiz, M. J.,
LeBrun, L. A.,
Lang, S. C.,
and Linhardt, R. J.
(2001)
Biochemistry
40,
11518-11524[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Rathore, D.,
Sacci, J. B.,
de la Vega, P.,
and McCutchan, T. F.
(2002)
J. Biol. Chem.
277,
7092-7098[Abstract/Free Full Text]
|
| 36.
|
Nussenzweig, R. S.,
and Zavala, F.
(1997)
N. Engl. J. Med.
336,
128-130[Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G. Mlambo and N. Kumar
Transgenic Rodent Plasmodium berghei Parasites as Tools for Assessment of Functional Immunogenicity and Optimization of Human Malaria Vaccines
Eukaryot. Cell,
November 1, 2008;
7(11):
1875 - 1879.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Garcia, A. Puentes, and M. E. Patarroyo
Developmental Biology of Sporozoite-Host Interactions in Plasmodium falciparum Malaria: Implications for Vaccine Design
Clin. Microbiol. Rev.,
October 1, 2006;
19(4):
686 - 707.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Tewari, S. A. Ogun, R. S. Gunaratne, A. Crisanti, and A. A. Holder
Disruption of Plasmodium berghei merozoite surface protein 7 gene modulates parasite growth in vivo
Blood,
January 1, 2005;
105(1):
394 - 396.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Rathore, S. C. L. Hrstka, J. B. Sacci Jr., P. De la Vega, R. J. Linhardt, S. Kumar, and T. F. McCutchan
Molecular Mechanism of Host Specificity in Plasmodium falciparum Infection: ROLE OF CIRCUMSPOROZOITE PROTEIN
J. Biol. Chem.,
October 17, 2003;
278(42):
40905 - 40910.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|